

Richard Adams

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9055743/richard-adams-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

66
citations

5
h-index

8
g-index

15
ext. papers

132
ext. citations

5.7
avg, IF

1.26
L-index

#	Paper	IF	Citations
11	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.. <i>Clinical Trials</i> , 2022 , 174077452211069879	2.2	1
10	Reply to A. Kurreck et al and M.S. Copur et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102806	2.2	0
9	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395	9.7	3
8	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
7	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2
6	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). <i>Radiation Oncology</i> , 2021 , 16, 163	4.2	0
5	Inhibition of WEE1 Is Effective in - and -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3705-3715	2.2	11
4	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3693-3704	2.2	5
3	HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 944-954	9.7	7
2	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , 2018 , 102, 31-39	7.5	14
1	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20